JAMA Network Home
Sign In
Research Letter

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer

JAMA Oncology 10.1001/jamaoncol.2025.4736

November 20, 2025 at 11:00 AM EST

Read the full article

This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with -amplified biliary tract cancer with a HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up.

Corresponding Author: James J. Harding, MD, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065 (hardinj1@mskcc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.4736?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=112025

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks